Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with Pinus halepensis Bark Extract

Acute radiodermatitis is the most common side effect in non-melanoma skin cancer patients undergoing radiotherapy. Nonetheless, despite the ongoing progress of clinical trials, no effective regimen has been found yet. In this study, a non-woven patch, comprised of electrospun polymeric micro/nanofib...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-05, Vol.13 (11), p.2596
Main Authors: Kyritsi, Aikaterini, Kikionis, Stefanos, Tagka, Anna, Koliarakis, Nikolaos, Evangelatou, Antonia, Papagiannis, Panagiotis, Stratigos, Alexandros, Karalis, Vangelis, Dallas, Paraskevas, Vitsos, Andreas, Ioannou, Efstathia, Roussis, Vassilios, Rallis, Michail
Format: Article
Language:English
Subjects:
Adverse events
Aluminum
Anti-inflammatory agents
Bark
Biological activity
Cancer therapies
Cellulose acetate
Clinical medicine
Clinical trials
Collectors
Dermatitis
Drug dosages
Erythema
Image processing
Inflammation
Medical equipment
Melanin
Melanoma
Patients
Pinus halepensis
Plant extracts
Prophylaxis
Radiation therapy
Scanning electron microscopy
Skin cancer
Skin carcinoma
Topical application
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute radiodermatitis is the most common side effect in non-melanoma skin cancer patients undergoing radiotherapy. Nonetheless, despite the ongoing progress of clinical trials, no effective regimen has been found yet. In this study, a non-woven patch, comprised of electrospun polymeric micro/nanofibers loaded with an aqueous extract of Pinus halepensis bark (PHBE), was fabricated and clinically tested for its efficacy to prevent radiodermatitis. The bioactivity of the PHBE patch was evaluated in comparison with a medical cream indicated for acute radiodermatitis. Twelve volunteer patients were selected and randomly assigned to two groups, applying either the PHBE patch or the reference cream daily. Evaluation of radiation-induced skin reactions was performed during the radiotherapy period and 1 month afterwards according to the Radiation Therapy Oncology Group (RTOG) grading scale, photo-documentation, patient-reported outcomes (Visual Analog Scale, questionnaire), biophysical measurements (hydration, transepidermal water loss, erythema, melanin), and image analysis. In contrast with the reference product, the PHBE patch showed significant anti-inflammatory activity and restored most skin parameters to normal levels 1 month after completion of radiation therapy. No adverse event was reported, indicating that the application of the PHBE patch can be considered as a safe medical device for prophylactic radiodermatitis treatment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13112596